These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 32296957)

  • 1. Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer.
    Lo Russo G; Facchinetti F; Tiseo M; Garassino MC; Ferrara R
    Curr Oncol Rep; 2020 Apr; 22(5):41. PubMed ID: 32296957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer.
    Kas B; Talbot H; Ferrara R; Richard C; Lamarque JP; Pitre-Champagnat S; Planchard D; Balleyguier C; Besse B; Mezquita L; Lassau N; Caramella C
    JAMA Oncol; 2020 Jul; 6(7):1039-1046. PubMed ID: 32525513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction model for hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitors.
    Choi YJ; Kim T; Kim EY; Lee SH; Kwon DS; Chang YS
    Thorac Cancer; 2020 Oct; 11(10):2793-2803. PubMed ID: 32779394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Advances in Hyperprogressive Disease in Patients 
with Advanced Non-small Cell Lung Cancer Treated with Immunotherapy].
    Yao S; Shi K; Zhang Y
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):271-278. PubMed ID: 33910275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis.
    Chen Y; Hu J; Bu F; Zhang H; Fei K; Zhang P
    BMC Cancer; 2020 Jul; 20(1):707. PubMed ID: 32727409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs).
    Liu J; Wu Q; Wu S; Xie X
    Clin Transl Oncol; 2021 Sep; 23(9):1782-1793. PubMed ID: 33847923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Definition, Incidence, and Challenges for Assessment of Hyperprogressive Disease During Cancer Treatment With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
    Park HJ; Kim KW; Won SE; Yoon S; Chae YK; Tirumani SH; Ramaiya NH
    JAMA Netw Open; 2021 Mar; 4(3):e211136. PubMed ID: 33760090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperprogressive Disease in Patients with Non-Small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of
    Castello A; Rossi S; Mazziotti E; Toschi L; Lopci E
    J Nucl Med; 2020 Jun; 61(6):821-826. PubMed ID: 31862803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
    Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH
    BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know.
    Camelliti S; Le Noci V; Bianchi F; Moscheni C; Arnaboldi F; Gagliano N; Balsari A; Garassino MC; Tagliabue E; Sfondrini L; Sommariva M
    J Exp Clin Cancer Res; 2020 Nov; 39(1):236. PubMed ID: 33168050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Redefining Clinical Hyperprogression: The Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy.
    Djunadi TA; Oh Y; Lee J; Yu J; Chung LI; Lee Y; Kim L; Hong T; Lee S; Shah Z; Park JH; Yoon SM; Chae YK
    Clin Lung Cancer; 2024 Jun; 25(4):365-375.e14. PubMed ID: 38644088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of hyperprogression based on volumetry in non-small cell lung cancer after immune checkpoint inhibitor treatment.
    Kim J; Kim T; Jang TW; Kang H; Kim MH; Yoon SH; Son CH; Lee HK; Kim HK; Lee SY; Shin KC; Han JY; Kang EJ
    Thorac Cancer; 2022 Aug; 13(15):2170-2179. PubMed ID: 35785522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature.
    Grecea M; Marabelle A; Ammari S; Massard C; Champiat S
    Oncologist; 2020 May; 25(5):369-374. PubMed ID: 32091646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lung metastasis and lymph node metastasis are risk factors for hyperprogressive disease in primary liver cancer patients treated with immune checkpoint inhibitors.
    Xiao LS; Li QM; Hu CY; Cui H; Hong C; Huang CY; Li RN; Dong ZY; Zhu HB; Liu L
    Ann Palliat Med; 2021 Nov; 10(11):11244-11254. PubMed ID: 34670386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis.
    Takamori S; Komiya T; Powell E
    Cancer Med; 2021 Feb; 10(3):923-932. PubMed ID: 33340271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proposal for multiple new lesions as complement of hyperprogressive disease in NSCLC patients treated with PD-1/PD-L1 immunotherapy.
    Wang M; Huang H; Xu Z; Li Z; Shen L; Yu Y; Lu S
    Lung Cancer; 2022 Nov; 173():28-34. PubMed ID: 36116167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management and outcomes of non-small cell lung cancer patients with rapid progression under second-or-more-line immune checkpoint inhibitors: ERORECI study (GFPC 2016-04).
    Vergnenegre A; Geier M; Guisier F; Lamy R; Comet B; Le Garff G; Do P; Janicot H; Morel H; Decroisette C; Andre M; Falchero L; Paleiron N; Monnet I;
    Cancer Med; 2020 Jan; 9(2):432-439. PubMed ID: 31747137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anlotinib succeeded in rescue therapy for hyperprogression induced by immune checkpoint inhibitors: a case report.
    Chen L; Liu D; Zhang Y; Jia Y; Zhao X; Liu M; Kong T
    Immunotherapy; 2023 Jun; 15(9):631-639. PubMed ID: 37020412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical patterns of response and progression in the era of immunotherapy combinations.
    Ferrara R; Matos I
    Future Oncol; 2020 Aug; 16(23):1707-1713. PubMed ID: 32687405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperprogressive disease: A distinct pattern of progression to immune checkpoint inhibitors.
    Toki MI; Syrigos N; Syrigos K
    Int J Cancer; 2021 Jul; 149(2):277-286. PubMed ID: 33300601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.